; (D) timely communication regarding a potential shortage or other supply chain disruption; and (E) the application of rules and processes of the Food and Drug Administration to the Department. (5) To include any information in the joint medical estimate of the Department or a similar report that highlights information that would be classified as sensitive or requiring a security classification above unclassified. (6) To develop a plan for the allocation of scarce pharmaceutical resources within the Department during a supply chain disruption and potential conflicts with competitors highlighted in the national defense strategy. (7) To develop a plan for stockpiling essential medications to ensure availability of a 180-day supply during an armed conflict or other supply chain disruption. (8) To develop a plan that mitigates vulnerabilities to active pharmaceutical ingredient supply chains and reduces dependence on active pharmaceutical ingredients from foreign sources. (e) Briefings (1) Initial briefing Not later than 180 days after the date of the enactment of this Act, the Secretary shall submit to the Committees on Armed Services of the Senate and House of Representatives an interim briefing on the organization, activities, plans, actions and milestones of the working group. (2) Annual briefing Not later than September 30 of each year, beginning in 2025 and ending in 2028, the Secretary shall submit to the Committees on Armed Services of the Senate and House of Representatives a briefing describing the activities, funding, plans, actions, and milestones of the working group, and other matters determined by the Secretary, during the preceding year. (f) Termination The working group shall terminate on September 30, 2028. C Studies, Briefings, Reports, and Other Matters 721. Modification of partnership program for military trauma care and research Section 736 of the James M. Inhofe National Defense Authorization Act for Fiscal Year 2023 ( Public Law 117–263